# Secondary Adjuvant Long Term Study With Arimidex

> **NCT00295620** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 3484 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Anastrozole

## Key facts

- **NCT ID:** NCT00295620
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03-01
- **Primary completion:** 2017-06-30
- **Final completion:** 2017-06-30
- **Target enrollment:** 3484 (ACTUAL)
- **Last updated:** 2019-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00295620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00295620, "Secondary Adjuvant Long Term Study With Arimidex". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00295620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*